Aditya Bagrodia

The other end of the spectrum is, you know, maybe even extrapolate from some of the stampede data where it's radiation, hormones, Abby, and, you know, you can make a case in a young, healthy person, aggressive disease that, that, and even doing an advent setting is not totally off the wall. I think again, extrapolating,

The other end of the spectrum is, you know, maybe even extrapolate from some of the stampede data where it's radiation, hormones, Abby, and, you know, you can make a case in a young, healthy person, aggressive disease that, that, and even doing an advent setting is not totally off the wall. I think again, extrapolating,

The other end of the spectrum is, you know, maybe even extrapolate from some of the stampede data where it's radiation, hormones, Abby, and, you know, you can make a case in a young, healthy person, aggressive disease that, that, and even doing an advent setting is not totally off the wall. I think again, extrapolating,

So we recently reviewed in one of our journal clubs, how do we kind of personalize this beyond PSA, doubling time, leasing score margins and so forth. And there seems to be some emerging data on biomarkers. Are you guys using that at all to inform timing, PSA levels, ADT, yes, no? Or do you think that's still kind of early phase?

So we recently reviewed in one of our journal clubs, how do we kind of personalize this beyond PSA, doubling time, leasing score margins and so forth. And there seems to be some emerging data on biomarkers. Are you guys using that at all to inform timing, PSA levels, ADT, yes, no? Or do you think that's still kind of early phase?

So we recently reviewed in one of our journal clubs, how do we kind of personalize this beyond PSA, doubling time, leasing score margins and so forth. And there seems to be some emerging data on biomarkers. Are you guys using that at all to inform timing, PSA levels, ADT, yes, no? Or do you think that's still kind of early phase?

Exactly. Deciphering Arteria. You got it.

Exactly. Deciphering Arteria. You got it.

Exactly. Deciphering Arteria. You got it.

So clinical trial through music coming to you, coming soon to a site near you, probably?

So clinical trial through music coming to you, coming soon to a site near you, probably?

So clinical trial through music coming to you, coming soon to a site near you, probably?

That's awesome. That's awesome. So you mentioned timing, and I think, you know, I take that to mean PSA level, you know, so functionally they're there. Talk a little bit about who, when.

That's awesome. That's awesome. So you mentioned timing, and I think, you know, I take that to mean PSA level, you know, so functionally they're there. Talk a little bit about who, when.

That's awesome. That's awesome. So you mentioned timing, and I think, you know, I take that to mean PSA level, you know, so functionally they're there. Talk a little bit about who, when.

So I don't know if this comes across your desk periodically, post-prostatectomy, let's say maybe three, four years ago, biochemical recurrence, they've been staged and they've got a pelvic lymph node and they really, for whatever reason, are averse to radiation. Can you talk a little bit about salvage and lymphadenectomy, what your thoughts, opinions are? Oof sounds about right.

So I don't know if this comes across your desk periodically, post-prostatectomy, let's say maybe three, four years ago, biochemical recurrence, they've been staged and they've got a pelvic lymph node and they really, for whatever reason, are averse to radiation. Can you talk a little bit about salvage and lymphadenectomy, what your thoughts, opinions are? Oof sounds about right.

So I don't know if this comes across your desk periodically, post-prostatectomy, let's say maybe three, four years ago, biochemical recurrence, they've been staged and they've got a pelvic lymph node and they really, for whatever reason, are averse to radiation. Can you talk a little bit about salvage and lymphadenectomy, what your thoughts, opinions are? Oof sounds about right.

Yeah, yeah. I would say more early on in my career.

Yeah, yeah. I would say more early on in my career.